Halberd Corp Stock Price, News & Analysis

Halberd Corporation (OTC PINK: HALB) has gained media attention from WKBN, a local CBS affiliate, for its revolutionary research at Youngstown State University (YSU) on disease treatment technologies. The company focuses on eliminating disease antigens related to conditions like Alzheimer's Disease and PTSD via a unique methodology that avoids bodily exposure. The research, led by Dr. William Sturrus at YSU, aims to establish proof of concept for Halberd's patent-protected technology, which could change global medical practices.

Halberd's CTO emphasized the method's rapid efficacy and safety compared to traditional treatments.

Halberd Corporation (OTC PINK:HALB) has appointed Dr. Ned Kronfol to its Scientific Advisory Board, enhancing its focus on extracorporeal treatment for blood-borne diseases. Dr. Kronfol's expertise will expedite advancements in tackling conditions like septicemia and cancer. The company emphasizes its strategic positioning in a high-demand healthcare area, where it has strong patent protection. Ongoing experiments at various universities are aimed at proof-of-concept for their patented methods. The corporation also plans to initiate FDA applications following initial successes in research.

Halberd Corporation (OTC PINK:HALB) has announced the shipment of its Vita-Shield-Max^TM nutraceutical product, coinciding with a rise in Covid-19 cases due to the Delta Variant. CEO William A. Hartman indicated that sales will commence shortly, with purchasing details to follow. The company previously released a 120-page compilation of medical articles supporting Vita-Shield-Max. Halberd holds exclusive rights to several patents for treatments related to COVID-19, acknowledging ongoing risks and uncertainties linked to the pandemic and its effect on operations.

Halberd Corporation (OTC PINK:HALB) announces a significant breakthrough in eliminating infectious diseases using a patented laser technique. The company successfully eradicated E. Coli bacteria in collaboration with Youngstown State University and Arizona State University, marking the first use of tuned laser technology for disease antigen eradication. The innovative method includes a variation of dialysis to expose bodily fluids to laser or RF energy, aiming to provide effective treatments for infectious diseases and potentially Alzheimer's Disease and PTSD.

Halberd Corporation (OTC PINK:HALB) announced the shipment of samples of metallic nanoparticles conjugated to Alzheimer's Disease antibodies to Youngstown State University. This follows promising initial tests involving metal conjugated antibodies against E. coli. The next step is eradicating these conjugated AD building blocks using Halberd's proprietary laser eradication process. CEO William Hartman stated that further development will focus on proteins associated with PTSD and Chronic Traumatic Encephalopathy. The company is also awaiting a more powerful radio frequency unit for parallel experimentation.

Halberd Corporation (OTC PINK: HALB) has shifted focus from COVID-19 research to tackling Alzheimer's Disease and other conditions due to decreased COVID cases. Collaboration with Youngstown State University and others aims to develop proprietary antibody technologies. Stock performance declined in Q2; however, plans for an OTCQB listing, launching an immune support product (Vita-Shield-Max™), and innovative research are expected to boost future performance. The company has filed multiple patents to strengthen its market position.

Halberd Corporation (OTC PINK:HALB) announces a breakthrough method for removing disease-causing antigens without using antibody-conjugated metallic nanoparticles. This new technique utilizes standard medical equipment, promising to lower treatment costs and simplify stock management. The initial focus will be Alzheimer's Disease, targeting key antigens and inflammatory cytokines. The development process is expedited by provisional patent applications. CEO William A. Hartman expressed optimism about market acceptance and commercial opportunities, enhancing Halberd's potential for growth.

Halberd Corporation (OTC PINK:HALB) has advanced its proprietary technology to Stage 4 in tackling Alzheimer's Disease, a condition impacting over 40 million globally. The company's method aims to eliminate the antibody-disease complex using radiofrequency waves and lasers. Steps 1-3 have been completed, with Step 4 in progress at Youngstown State University, overseen by Dr. William G. Sturrus. Halberd's team is addressing unique challenges to ensure the efficacy of their treatment. The company has expanded its target antigens list, enhancing success probability.

Halberd Corporation (OTC PINK:HALB) has developed a novel method for extricating Alzheimer's Disease-related proteins from Cerebral Spinal Fluid (CSF) using gold-coated iron oxide nanoparticles.

This technique aims to combat neurofibrillary tangles linked to Alzheimer's Disease, with initial tests planned at Youngstown State University using E.coli. The company is advancing towards animal safety tests, focusing on eradicating harmful antigens from CSF to potentially slow the disease's progression. The projected increase in Alzheimer's cases reinforces the significance of this research.